Target of replication: *A priori* experimental protocols, materials, and confirmatory analysis plans were peer reviewed, [pre-registered][1], and published by [*eLife*][2]. This component includes all primary and QC data for protocols 4, 5, & 6 of the replication of [Liu et al. 2011][3]. These experiments include: ### Contents ### [Figures component][4], contains a visualization of the results. These figures are the same as can be found in the Replication Study and include Figure 2 and Figure 2 - figure supplement 1, which display the effect of miR-34a expression on tumor growth and CD44 expression and latency and individual tumor xenografts, respectively. [Statistical Analysis Component][5], contains the statistical analysis scripts used to analyze all data for protocols 4, 5, and 6. They include Randomization, Volume and Latency analysis, and Tumor weight anlaysis. [Data Component][6], contains data generated from the experimental work related to protocols 4, 5, & 6, which relate to the effects of miR-34a on tumor growth and CD44 expression in LAPC4 tumor tissue. [Methods Component][7], contains the methods relating to all protocols in this section. [Maintenance and purification of LAPC4 xenograft prostate tumors Component][8] [Quality Control Component][9], contains the results of both STR profiling and mycoplasma testing related to these protocols. [1]: https://osf.io/4psr3/ [2]: https://elifesciences.org/articles/06434 [3]: http://www.nature.com/articles/nm.2284 [4]: https://osf.io/2axzh/wiki/home/ [5]: https://osf.io/vmqds/wiki/home/ [6]: https://osf.io/h37rf/wiki/home/ [7]: https://osf.io/exq24/wiki/home/?edit&view&menu [8]: https://osf.io/4f3rq/wiki/home/?edit&view&menu [9]: https://osf.io/6u42f/wiki/home/?edit&view&menu